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Objective: In infants undergoing closure of perimembranous ventricular septal
defects, cardiopulmonary bypass remains one of the factors that prolongs hospital
stay and morbidity. A new technique was used to close the defects under echocar-
diographic guidance without cardiopulmonary bypass to prevent the deleterious
effects of bypass.
Methods: Recently, the Amplatzer membranous ventricular septal defect device
(AGA Medical Corp, Golden Valley, Minn) was introduced. The device has a
double-disc design with a short connecting waist. The left ventricular disc has an
eccentric design to prevent encroachment on the aortic valve leaflets. Eight Yucatan
miniature pigs with naturally occurring perimembranous ventricular septal defects
underwent closure of the defect in the operating room by using the perventricular
technique. After median sternotomy, a purse-string suture was placed on the free
wall of the right ventricle. An angiocatheter was advanced in the right ventricle, and
through the catheter, a wire was advanced from the right ventricle through the
ventricular septal defect into the left ventricle. A delivery sheath and the dilator were
advanced over the wire. The wire and catheter were removed, and an appropriately
sized Amplatzer membranous device was advanced through the sheath. The device
was deployed under echocardiographic guidance with the heart beating.
Results: The procedure was successful in all animals. There was no incidence of
device embolization, heart block, or aortic insufficiency. Angiograms at 3 and 6
months revealed no residual defects and no aortic insufficiency. Pathologically, the
devices were completely endothelialized when examined grossly.
Conclusions: The perventricular technique appears to be excellent for closure of
perimembranous ventricular septal defects in the operating room. The technique
might be feasible in smaller babies, who are high-risk candidates for closure in the
catheterization laboratory. Cardiopulmonary bypass and prolonged hospital stay are
avoided.
Perimembranous (or conoventricular) ventricular septal defects (PM-VSDs) are among the most common congenital cardiac malforma-tions.1,2 Closure is routinely performed with the patient undergoingcardiopulmonary bypass (CPB), with excellent results.2-4 CPB andsternotomy are important factors that might lead to increased postop-erative morbidity, prolonged hospital stay, and possible late neuro-
cognitive impairment.5 The long-term effects of CPB remain elusive, and its effects
are more pronounced in infants than in patients of older age.6 We describe a new
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technique to close PMVSDs in which the defects were
closed under echocardiographic guidance without CPB.
Methods
All animals received humane care in compliance with the “Guide
for the Care and Use of Laboratory Animals” prepared by the
Institutes of Laboratory Animal Resources and published by the
National Institute of Health (publication no. 86-23, revised 1985).
The study was approved by the Institutional Animal Care and Use
Committee of the University of Nebraska Medical Center, Omaha,
Neb.
Animal Model
Yucatan miniature pigs with naturally occurring PMVSDs were
used in this study. These pigs have naturally occurring PMVSDs
that are similar to those of human beings. The defects are located
under the anteroseptal commissure of the tricuspid valve and are
subaortic in location when viewed from the left ventricular side.
Amplatzer PMVSD Occluder
The Amplatzer PMVSD Occluder device (AGA Medical Corp,
Golden Valley, Minn) is made of 0.004-inch Nitinol wire mesh
(Figure 1). The wires are shaped to form double discs, with a short
connecting waist measuring 1.5 mm. Dacron is sewn inside the
discs to decrease shunting through the wire mesh. The device is
self-expandable and fully retrievable to the point of release. The
size of the device corresponds to the waist of the device. The edge
of the left ventricular disc, which is to face the aortic valve, is only
0.5 mm larger than the waist to prevent impingement of the aortic
valve. The edge of the disc opposite the aortic valve is 5 mm larger
than the waist. The right ventricular disc is 2 mm larger than the
waist all around its circumference. A female screw is welded in the
center of the right disc for attachment to the delivery cable. The
device is designed to be deployed percutaneously from the right
ventricular side with a slightly complex delivery system to ensure
that the device orientation is maintained (the flat edge toward the
aortic valve). For the perventricular approach, however, a simple
delivery sheath is used because the device can be easily rotated at
the time of deployment. The device is available in sizes ranging
from 4 to 18 mm, with 2-mm increments. The delivery sheath size
is dependent on the size of the device and ranges from 6F to 9F.
Perventricular Technique
The pigs’ weight ranged from 17 to 53 kg, with 7 pigs weighing
less than 25 kg. All pigs except one were less than 3 months old
at the time of the procedure.
The perventricular technique for closure of muscular ventricu-
lar septal defects (VSDs) has been described in previous studies.7,8
The procedure remains the same for PMVSDs. The chest was
opened through a median sternotomy. The pericardium was cra-
dled. A purse-string suture of 4-0 or 5-0 Prolene sutures (Ethicon,
Somerville, NJ) was placed on the free wall of the right ventricle.
Epicardial echocardiography was performed to measure the exact
size and location of the PMVSD. The integrity of the aortic valve
was evaluated. An angiocatheter was passed into the right ventricle
through the free wall of the right ventricle, and the needle was
removed (Figure 2). A 0.035-inch floppy or glide wire was ad-
vanced through the angiocatheter and aimed toward the PMVSD.
The PMVSD was crossed, and the wire was advanced through the
aortic valve in the ascending aorta (Figure 3). The dilator was
removed, and an appropriately sized delivery sheath was advanced
over the wire into the ascending aorta (Figure 4). The wire and the
dilator were removed, and the sheath was allowed to back bleed to
ensure there was no air entrapment. The Amplatzer PMVSD
device was immersed in saline and screwed on to the delivery
cable. The device was loaded with the help of a loader. The loader
was introduced into the delivery sheath, and the device was ad-
vanced to the tip of the sheath (Figure 5). The sheath was gently
pulled back until the tip was in the left ventricle, just under the
aortic valve (Figure 6). Under echocardiographic guidance, the left
disc was deployed; the sheath and the device were pulled back
until the left disc approximated the ventricular septum (Figure 6).
The device was gently rotated only if the flat part of the disc was
not directly under the aortic valve. The waist and the right disc
Figure 1. Amplatzer membranous VSD occluder attached to the
delivery catheter.
Figure 2. Angiocatheter (b) inserted through the purse-string su-
ture (a) on the right ventricular free wall. A wire is advanced
through the angiocatheter and aimed toward the VSD (inset). Ao,
Aorta; RV, right ventricle; LV, left ventricle; PA, pulmonary artery;
SVC, superior vena cava.
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were deployed while maintaining fair traction on the delivery cable
(Figure 7, A). The position of the device was checked, the aortic
valve was evaluated for aortic insufficiency, and the device was
released by rotating the delivery cable anticlockwise (Figure 7, B).
The sheath and the delivery cable were pulled out of the right
ventricle, and the purse-string suture on the right ventricle free
wall was tied. Epicardial echocardiography was used to evaluate
tricuspid or aortic regurgitation. The pericardium was partially
closed, and a chest tube was placed in the mediastinum. The
sternum was approximated with the help of sternal wires. The
chest wall was closed in routine fashion. The animal was extubated
on the operating room table. The chest tube was removed before
the animal was transported back to the recovery room.
A total of 8 Yucatan pigs underwent closure of PMVSDs. Two
pigs were killed immediately after the procedure. The remaining 6
pigs were kept alive for 6 to 7 months. The size of the PMVSD and
the size of the sheaths and devices are outlined in Table 1.
Cardiac catheterization and angiography were performed at 3
and 6 months. The animals were killed after the 6-month angio-
gram. The heart was subjected to gross and microscopic examina-
tion.
Results
The procedure was successful in all animals. There was no
incidence of device embolization or heart block. In one pig
Figure 3. The wire (c) is advanced through the VSD and aortic
valve to the ascending aorta. Ao, Aorta; RV, right ventricle; LV, left
ventricle.
Figure 4. The delivery sheath (d) and the dilator are advanced
over the wire into the aorta. Ao, Aorta; RV, right ventricle; LV, left
ventricle.
Figure 5. The Amplatzer membranous occluder (e) is advanced
through the delivery sheath after removing the dilator. Ao, Aorta;
RV, right ventricle; LV, left ventricle.
Figure 6. The delivery sheath is pulled until the tip is just under
the aortic valve and the left disc is deployed (A). After deploying
the left disc completely (B), the delivery sheath is pulled back to
approximate the left disc to the ventricular septum (C). Ao, Aorta;
RV, right ventricle; LV, left ventricle.
Figure 7. The right disc is deployed while keeping traction on the
delivery cable (A). The device is released by rotating the delivery
cable counterclockwise (B). Ao, Aorta; RV, right ventricle; LV, left
ventricle.
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the initial device had to be removed before it was released
because of residual shunt. The device was replaced with a
larger device. One pig had a PMVSD and an outlet (subar-
terial) VSD and hence required 2 devices. Angiograms
obtained at 3 and 6 months after device placement showed
no residual defect (Figure 8) or aortic insufficiency (Figure
9).
After the heart was explanted, saline was injected into
the right ventricle to assess tricuspid valve leaflet coapta-
tion. Complete coaptation was seen in all pigs. Gross ex-
amination of the heart from the left ventricular and right
ventricular sides revealed complete coverage of the devices
with the neoendocardium (Figures 10-12). The central area
of the device was covered by a dense fibrocollagenous
tissue. There were numerous inflammatory cells composed
of foreign-body giant cells and histiocytes. The Dacron
fibers were also surrounded by the foreign-body giant cells
and histiocytes (Figure 13). There was extension of the scar
tissue from the wire mesh to the surrounding cardiac tissue.
The area adjacent to the aortic valve showed fibrosis and
endothelial-like cells in the focal region. On the tricuspid
valve side, valve adhesion to the edge of the device was
seen in 3 pigs. The integrity of the tricuspid valve appeared
preserved. Cartilaginous metaplasia of the myocardium to-
ward the edge of the device was seen. There was no evi-
dence of infection. All these findings were typical responses
of the myocardium to the device.
Discussion
Intraoperative device closure of muscular VSDs has been
described previously in the literature.9,10 However, all pro-
cedures were performed during CPB. The results were not
as good as expected initially,9 but slightly improved results
were reported later.10 In the previous studies the main
reason for disappointing results were use of a non–self-
centering device, a rigid delivery system, and no help from
transesophageal or epicardial echocardiography during de-
vice placement because the heart was flaccid while the
patient was under CPB.
The perventricular technique was introduced in 1997,
and the first patient who underwent intraoperative device
closure of a muscular VSD without CPB was reported by us
in 1998.7 In 1999, we reported intraoperative device closure
of a PMVSD through a left thoracotomy, but the results
were not encouraging because a concentric device was
used.8
Cumulatively, more than 19 patients have undergone
closure of the muscular VSD with this technique, with good
results.11,12 The success of this technique, when compared
with that of previous attempts, lies in several factors. The
first factor is that CPB is not used. The second factor is that
the device placement and residual shunt can be evaluated by
means of echocardiography because the heart is beating
during the procedure. The third factor is that the delivery
sheath is malleable and small in size when compared with
that used in the previous experiments. The fourth factor is
TABLE 1. Device and defect size
PMVSD size Sheath size Device size
8 mm 7F 10 mm
4 mm and 8 mm 7F 6 mm and 10 mm
3 mm 6F 4 mm
5 mm 6F 6 mm
11 mm 7F 12 mm
6 mm 6F 8 mm
5 mm 6F 6 mm
7 mm 7F 8 mm
PMVSD, Perimembranous ventricular septal defect.
Figure 8. The delivery cable is pulled out of the right ventricle
and the purse-string suture is tied. Ao, Aorta; RV, right ventricle;
LV, left ventricle.
Figure 9. Left ventricular angiogram at 7 months’ follow-up: no
residual shunt is seen. The arrow points toward the device.
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the design of the device. The Amplatzer device is a self-
centering, self-expanding, and fully retrievable device with
a circular design. It is devoid of hooks or arms. The length
of the connecting waist is small, which helps the device to
approximate to the ventricular septum.
The last several years have seen significant advancement
in minimally invasive techniques and increased use of de-
vices.12-16 The deleterious effects of CPB in adult patients
range from microbubbles, total body inflammatory re-
sponses, and postoperative cerebral dysfunction.17 The del-
eterious effects of CPB in pediatric patients without com-
plex lesions remain unknown; however, transient and
permanent neuropsychiatric injury has been reported in as
many as 25% of patients.6 There is also risk of silent brain
injury, even in patients who underwent isolated secundum
atrial septal defect closure, as reported by Visconti and
colleagues.18 Therefore avoiding CPB might decrease post-
operative morbidity and mortality.
PMVSDs are among the most common congenital car-
diac lesions, and hemodynamically symptomatic patients
require closure earlier in infancy. These patients are failing
to thrive because of congestive heart failure. Catheterization
laboratory closure of the PMVSD in these patients is diffi-
cult and carries a high risk of complications because of large
sheath size relative to patient size. The catheters are difficult
to manipulate, which increases cardiac catheterization time,
radiation, and risk of arrhythmia. The perventricular ap-
proach simplifies PMVSD closure. The potential complica-
tions of cardiac catheterization and fluoroscopy are avoided
because the procedure is performed under echocardio-
Figure 10. Ascending aortogram at 7 months’ follow-up reveals
no aortic insufficiency. The arrow points toward the device.
Figure 11. Amplatzer PMVSD occluder in situ 6 months after
placement from the right ventricular side. The whole device is
covered with glistening neoendocardium. The arrow points to-
ward the device.
Figure 12. Device in situ from the left ventricular aspect. The
device is completely covered by the neoendocardial layer. The
arrow points toward the device.
Figure 13. Higher magnification (2.5) of the middle portion of
the implanted device. A layer of neoendocardium (red arrow)
covers the device’s wire mesh (green arrow). The Dacron fibers
are surrounded by the granulation tissue, and vascularity is
evident between the filaments of Dacron.
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graphic guidance. The procedure is simplified because there
are no acute turns of the catheter inside the heart. Because
the procedure is performed on the beating heart, the proce-
dure time is significantly reduced; the closure rate and the
integrity of the aortic valve are evaluated before the device
is released. Postoperatively, these patients are expected to
recover faster than patients who have undergone closure
during CPB, as has been seen when patients underwent
muscular VSD closure with this technique.
In summary, we believe that the perventricular technique
is feasible and might open other avenues that can be used to
close septal defects by using minimally invasive techniques,
such as robotic surgery. Avoidance of CPB will decrease the
immediate postoperative and long-term potential complica-
tions.
This study has some limitations. We did not evaluate
tricuspid valve insufficiency by means of echocardiography
at the time of death. The decision was based on poor
transthoracic acoustics in pigs. The angiograms would have
been unreliable because to assess tricuspid insufficiency, we
had to cross the tricuspid valve with a catheter to perform an
angiogram. The coaptation of the tricuspid valve leaflet was
assuring after the heart was explanted.
Although there was no evidence of aortic valve insuffi-
ciency on the basis of angiography and no evidence of valve
injury on the basis of gross or microscopic examination,
there is potential for injuring the aortic valve with the
delivery sheath or catheters. Similarly, we did not see any
injury to the tricuspid valve, although the possibility exists.
The wires and catheters used in the procedure are the usual
catheters used during cardiac catheterizations in neonates
and infants. Hence the chance of injuring the cardiac valves
or other structures is low.
The risk of long-term problems with the aortic valve
remains unknown. Long-term follow-up will be needed in
human subjects. We do not believe it to be a problem
because the device does not encroach on the aortic valve.
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Discussion
Dr Emile A. Bacha (Chicago, Ill). Amin and colleagues per-
formed PMVSD closure in 8 large animals, which were kept alive
for 6 months. They were successful in all cases and have presented
solid angiographic and histologic evidence that this technique is
feasible and safe in the medium term. Dr Amin, I congratulate you
for pioneering the field of intraoperative device closure. I also
commend you on presenting your data to a surgical audience as
opposed to an interventional meeting. After all, surgeons have
been involved with VSD closure for more than 30 years.
On the basis of your data and the preliminary US Food and
Drug Administration trial data, it appears that device closure of a
membranous VSD is safe at medium term. However, the aortic
valve is at risk for either immediate injury or long-term dysfunc-
tion. Long-term results are awaited in that respect. I disagree with
your description of CPB as being deleterious. Most studies show-
ing the deleterious effects of CPB were done either in adults with
atherosclerosis or in neonates with complex malformations. Hav-
ing said that, I believe that perventricular device closure is here to
stay and that surgeons should firmly embrace and study this new
technology. As you know, we have now performed perventricular
muscular VSD closure in 6 patients, and all of those procedures
were successful. I have 3 questions for you.
What is your opinion of the long-term effect of the device on
aortic valve function given the proximity of the device? In neo-
nates and infants, do you think that the disks protruding in the
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outflow tract might result in outflow obstruction? I noticed that the
lowest weight of the pigs was 16 kg. Typically, the patients we
operate on would be much smaller than that.
The third question is, because of the need for precise position-
ing of the device, with the flat side toward the aortic valve, and
thus the need to rotate the entire delivery assembly, do you believe
that this technique would be easier to apply through a perventricu-
lar approach in the operating room, as you have shown, as opposed
to a percutaneous approach from the groin? Thank you very much.
Dr Amin. Thank you, Dr Bacha. As to your first question about
the long-term follow-up, as you mentioned, the pigs weighed
anywhere from 17 to about 53 kg. Excluding one pig that weighed
53 kg, all remaining pigs weighed less than 30 kg and were less
than 3 months old. Therefore they really were small in size and
young. During the follow-up period of 6 months, there was tre-
mendous weight gain. One of the pigs that weighed only 16 kg at
the time the device was placed weighed more than 100 kg at the
time of death. I think that is a significantly long follow-up period
in pig years. Therefore they really matured into adulthood, if you
will.
But in human terms, I am not sure what the long-term fol-
low-up will hold. If you do look at the devices that were placed in
1989 in muscular VSDs—and sometimes those devices were also
placed in the perimembranous area—although their immediate and
acute results were not very good, long-term data are lacking. I
totally agree with you that we will find out what the long-term
results are in about 5 to 10 years. China has performed almost 300
perimembranous VSD closures with this device over the last 212
years. During follow-up, they had 6 patients who had trace to mild
aortic insufficiency. Unfortunately, I cannot tell you exactly what
their criteria for trace or mild insufficiency are unless and until I
review the echocardiograms.
In regard to your second question about CPB, I simply believe
that no matter how simple or complex the patient’s condition is, no
CPB is preferable.
As to your last question about positioning the device, how the
flat edge has to face or should face the aortic valve, I agree with
you that it is easier to do in the operating room because we can
rotate the sheath very easily clockwise or anticlockwise as opposed
to when we are performing the procedure in the cardiac catheter-
ization laboratory because we lose the torque on the sheath. In the
operating room it is relatively easier.
Dr Ross M. Ungerleider (Portland, Ore). Zahid, you are to be
complimented on something very innovative, not just the use of a
device but also the concept of truly collaborative work. The
Institute of Medicine has been telling us for years that to improve
patient safety, we need to become more team oriented and multi-
disciplinary in our approach to disease, and for you to get out of
the silo of the catheterization laboratory and to begin to collaborate
with surgeons in the operating room might open up the doors for
several innovations for the treatment of congenital heart disease in
babies as we combine our efforts. We have done that with intra-
operative stenting and now with these devices. I have 2 questions
for you.
Tell us a little bit about the kind of anatomy that these Yucatan
pigs have with their perimembranous VSDs. It is my experience
that human infants can sometimes have very complex relationships
between the tricuspid valve chordal mechanisms and the VSD that
might make it somewhat difficult to position the device without
creating significant tricuspid insufficiency. Is the same kind of
chordal relationship complexity true of the Yucatan pigs?
The second question is, have you considered using this device
in an open fashion, although it does require the infants being
placed on bypass, to close multiple muscular VSDs, or even to
position it precisely in a perimembranous location, which might be
easier than sewing a patch in place?
Again, I congratulate you on the true innovation, which is the
collaboration with your surgical colleagues, because together I
suspect we could innovate terrific things in the future.
Dr Amin. Thank you, Dr Ungerleider. The anatomy of the
perimembranous VSDs in pigs is actually very similar to that seen
in human subjects. The complexity of the chordal attachment of
the septal leaflet of the tricuspid valve in pigs is very much similar
to the chordal attachment of the leaflets in human subjects. Our
pathology data revealed that some chordae were trapped under-
neath the right disc, but the tricuspid insufficiency was never more
than mild, which I believe is acceptable and similar to the surgical
results. The VSD is just under the anteroseptal commissure of the
tricuspid valve, just as it is in human subjects.
The only difference that pops in my mind at the current time is
that the pigs have a higher propensity for aneurysm formation and
hence possibly a higher chance of spontaneous closure. The pig
hearts have been examined by a few pathologists in the past, and
they found that the pig hearts were similar to human hearts.
In regard to your second question, although we have not looked
at closing the defects in an open fashion, I believe it will be very
much feasible, especially in patients with muscular VSDs. The
only disadvantage I can foresee is that we will not be able to
determine whether the patient has a residual defect because the
heart will be flaccid.
Dr Marian Zembala (Zabrze, Poland). I would compliment
your work for 2 reasons on the basis of our experience, closure of
12 patients with post-VSD by nonoperating field by interventional
cardiologists. We lost 12 patients; all of them were at higher risk.
That is why we did not decide on surgery. One we lost in the sixth
postoperative week because of multiorgan failure and septicemia
caused by long-term radiation instead of short-term radiation.
When you close an atrial septal defect, the VSD is much longer,
and I think this teamwork helped to avoid this long radiation.
Anyway, I think it is a good approach, even for more difficult
patients, such as those who have postinfarction VSD.
Dr Amin. Thank you.
Dr Carlos J. Troconis (Caracas, Venezuela). Congratulations
for your innovative technique. I have 2 questions. The first one is,
we have observed in those patients with a perimembranous VSD
that some of them do not have an infundibular ventricular infold
rim. And I noticed in your slides that these pigs have a rim of
muscle (septum) between the tricuspid valve and the aortic valve.
Therefore would the placement of your device sometimes be
difficult if there is a lack of such morphology?
The second question is, does the 3-dimensional echocardiog-
raphy enhance your technique?
Dr Amin. Thank you. I believe that you are asking me about
the rim of tissue that we find under the aortic valve. If there is a
complete absence of the rim, it is conceivable that the device might
impinge on the aortic valve and cause insufficiency or the patient
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might have a residual defect. The perimembranous VSD device
design has a flat edge, with the rim measuring only 0.5 mm more
than the disk. In addition, in phase I trials in the United States, all
patients with any evidence of aortic insufficiency will be excluded,
and the patient’s weight will have to be more than 8 kg. Therefore
hopefully we can avoid this potential complication. I believe that
this device is not going to be suitable for all the patients with
perimembranous VSDs.
Concerning your second question about the 3-dimensional
echocardiogram, I completely agree with you that it should en-
hance the visibility and precise placement, and we are working
with one company at the current time.
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